|
|
|
|
|
|
|
|
|
|
|
15.05.25 - 07:00
|
PeptiSystems and Asahi Kasei Bioprocess America enter exclusive global partnership for peptide synthesis (Cision)
|
|
|
PeptiSystems, a biotech company specializing in innovative manufacturing solutions for peptide and oligonucleotide drugs, has formed an exclusive global partnership with Asahi Kasei Bioprocess America (AKBA), a leading provider of advanced bioprocessing equipment solutions. The collaboration combines PeptiSystems' flow-through instrument platform with AKBA's high-performance column technology – giving customers a streamlined and reliable setup from the very first run.
[PeptiSystems-Asahi-Kasei-Bioprocess-America-global-partnership-peptide-synthesis.png]
As part of the partnership,...
|
|
|
|
|
|
|
|
|
|
|
|
|
24.04.25 - 14:54
|
Ken Shinomiya Becomes Leader of Asahi Kasei′s Healthcare Sector (Business Wire)
|
|
|
Leading the way for the sector's continued growth and commitment to improving patient outcomes
CHELMSFORD, Mass. & NOVI, Mich. & DÜSSELDORF, Germany & TOKYO--(BUSINESS WIRE)--Asahi Kasei has appointed Ken Shinomiya, President of Asahi Kasei Life Science, as the Leader of its Healthcare Sector succeeding Richard Packer. Under Shinomiya, Asahi Kasei's Healthcare Sector will further advance its portfolio and global presence of pharmaceuticals, life science, and critical care products and services.
Having served as Vice President of Strategy at ZOLL Medical Corporation from fiscal 2016 to fiscal 2017, Shinomiya became Head of the Bioprocess Division of Asahi Kasei Medical in April 2019 and President of Asahi Kasei Medical in April 2023. In April 2025, he was named President of Asahi Kasei Life Science, the successor company to the bioprocess business of Asahi Kasei Medical. With operations focused on products and services that support the manufacture of pharmaceuticals, the life science business has grown ...
|
|
|
|
|
|
|
16.04.25 - 13:03
|
Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDG (Business Wire)
|
|
|
GLM101 is the first disease-modifying therapeutic in development to treat PMM2-CDG, the most common congenital disorder of glycosylation
Data from the ongoing Phase 2 open-label study of GLM101 provide clinical proof of concept, showing improvement in ataxia, a key burden of disease in PMM2-CDG
Funding will support advancement of GLM101 into a randomized, placebo-controlled Phase 2b safety and efficacy study
SAN CARLOS, Calif.--(BUSINESS WIRE)--#CDG--Glycomine, Inc., a biotechnology company focused on developing transformative new therapies for orphan diseases, today announced a $115 million Series C financing to advance its lead candidate, GLM101, into a Phase 2b clinical trial. The financing was led by CTI Life Sciences Fund, funds managed by abrdn Inc., and Advent Life Sciences, alongside continued investment from existing investors, Novo Holdings, Sanofi Ventures, Abingworth, RiverVest Venture Partners, Sanderling Ventures, Chiesi Ventures, Remiges Ventures, and Asahi Kasei Ventures.
“We are excited...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
